Drug Profile
Research programme: neurodegenerative disorders therapeutics - Neurim Pharmaceuticals
Alternative Names: Neu-240; Neurodegeneration drug discovery - Neurim Pharmaceuticals; Neurodegeneration programme - Neurim PharmaceuticalsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Neurim Pharmaceuticals
- Class
- Mechanism of Action NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyskinesias; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dyskinesia in Israel
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Israel
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease(Adjunctive treatment) in Israel